Fraudsters who exploit LinkedIn to lure users into cryptocurrency investment schemes pose a "significant threat" to the platform and consumers, according to Sean Ragan, the FBI's special agent in charge of the San Francisco and Sacramento, California, field offices. From a report: "It's a significant threat," Ragan said in an exclusive interview. "This type of fraudulent activity is significant, and there are many potential victims, and there are many past and current victims." The scheme works like this: A fraudster posing as a professional creates a fake profile and reaches out to a LinkedIn user. The scammer starts with small talk over LinkedIn messaging, and eventually offers to help the victim make money through a crypto investment. Victims interviewed by CNBC say since LinkedIn is a trusted platform for business networking, they tend to believe the investments are legitimate. Typically, the fraudster directs the user to a legitimate investment platform for crypto, but after gaining their trust over several months, tells them to move the investment to a site controlled by the fraudster. The funds are then drained from the account.

The NY Times is running a story about Dwarf Fortress, an independently produced, ASCII-rendered fantasy game that thrives on its own uniqueness and has influenced countless other game developers (and runs on Linux). Quoting: "Though it may seem ungainly at first, the game’s interface — rendered in what are known as extended ASCII characters — has a sparse elegance. As seasons change, trees, represented by various symbols, shift from green to yellow. Goblins’ eyes appear as red quotation marks; if you shoot out an eye with an arrow, the symbol becomes an apostrophe. On a message board, one fan likened the ASCII experience in Dwarf Fortress to the immersive pleasures of reading a book: 'You can let your imagination fill in the gaps.' The community that has arisen around Dwarf Fortress is remarkable. Fans maintain an extensive wiki, which remains the game’s best (and, effectively, only) instruction manual, and which even Tarn and Zach admit to consulting. ... Perhaps most fascinating are the stories that fans share online, recounting their dwarven travails in detailed and sometimes illustrated narratives. In a 2006 saga, called Boatmurdered, fans passed around a single fortress — one player would save a game, send the file to another player and so on, relay-race style — while documenting its colorful descent into oblivion."

theodp writes "If you were a college prof, think you could successfully compete for the attention of a lecture hall of Mac-packing students? CS student Carolyn blogs that a debate has sprung up on her campus about whether it is acceptable to use a laptop in class. And her school is hardly alone when it comes to struggling with appropriate in-classroom laptop use (vendor/corporate trainers would no doubt commiserate). The problem, she says, is that the OCD Facebookers aren't just devaluing their own education — there's a certain distraction factor to worry about. 'Students,' she suggests, 'should also communicate with each other more and tell their classmates when their computer use bothers them. I'll admit it, when I'm trying to pay attention to the lecture, even someone's screensaver in the row ahead of me can be a major distraction.'"

RedEaredSlider writes "Researchers at the US Army Medical Research Institute of Infectious Diseases have found a class of drugs that could provide treatment for Ebola and Marburg hemorrhagic fever. The new drugs are called 'antisense' compounds, and they allow the immune system to attack the viruses before they can do enough damage to kill the patient. Travis Warren, research scientist at USAMRIID, said while the work is still preliminary -— the drugs have been tested only on primates — the results are so far promising. In the case of Ebola, five of eight monkeys infected with the virus lived, and with Marburg, all survived. The drugs were developed as part of a program to deal with possible bioterrorist threats, in partnership with AVI Biopharma."